17 Healthcare Stocks Moving In Monday's Pre-Market Session

Gainers

• Equillium, Inc. EQ shares rose 261.12% to $11.52 during Monday's pre-market session.

• electroCore, Inc. ECOR stock increased by 184.70% to $2.42.

• Altimmune, Inc. ALT shares moved upwards by 49.88% to $33.50.

• Xeris Pharmaceuticals, Inc. XERS stock rose 17.04% to $3.09. The most recent rating by Mizuho, on Apr 23, is at Buy, with a price target of $14.

• Sunesis Pharmaceuticals, Inc. SNSS shares increased by 12.62% to $0.31. According to the most recent rating by Oppenheimer, on Jun 24, the current rating is at Perform.

• Centogene, Inc. CNTG shares increased by 8.57% to $14.44. The most recent rating by Baird, on Apr 24, is at Outperform, with a price target of $20.

• Cassava Sciences, Inc. SAVA shares rose 8.54% to $3.62. According to the most recent rating by HC Wainwright & Co., on May 18, the current rating is at Neutral.

• BioNTech, Inc. BNTX stock moved upwards by 7.73% to $75.80. The most recent rating by SVB Leerink, on Jul 2, is at Market Perform, with a price target of $42.

• Tonix Pharmaceuticals, Inc. TNXP stock moved upwards by 7.56% to $0.69.

• Seres Therapeutics, Inc. MCRB shares moved upwards by 7.53% to $4.85.

Losers

• NextCure, Inc. NXTC stock declined 10.52% to $16 during Monday's pre-market session. According to the most recent rating by Benchmark, on Jun 1, the current rating is at Hold.

• Endologix, Inc. ELGX shares decreased by 5.56% to $0.26. According to the most recent rating by BTIG, on May 12, the current rating is at Neutral.

• Mesoblast, Inc. MESO stock declined 3.85% to $12.52. The most recent rating by HC Wainwright & Co., on May 28, is at Buy, with a price target of $21.

• Dynatronics, Inc. DYNT shares decreased by 3.49% to $0.83. The most recent rating by Aegis Capital, on May 19, is at Buy, with a price target of $1.

• 9 Meters Biopharma, Inc. NMTR shares decreased by 3.40% to $0.53.

• CHF Solutions, Inc. CHFS stock declined 3.31% to $0.59.

• Arbutus Biopharma, Inc. ABUS stock declined 3.23% to $1.80. The most recent rating by Wedbush, on May 19, is at Outperform, with a price target of $4.